These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 22275114)

  • 1. A gene signature identified using a mouse model of androgen receptor-dependent prostate cancer predicts biochemical relapse in human disease.
    Thompson VC; Day TK; Bianco-Miotto T; Selth LA; Han G; Thomas M; Buchanan G; Scher HI; Nelson CC; ; Greenberg NM; Butler LM; Tilley WD
    Int J Cancer; 2012 Aug; 131(3):662-72. PubMed ID: 22275114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutation of the androgen receptor causes oncogenic transformation of the prostate.
    Han G; Buchanan G; Ittmann M; Harris JM; Yu X; Demayo FJ; Tilley W; Greenberg NM
    Proc Natl Acad Sci U S A; 2005 Jan; 102(4):1151-6. PubMed ID: 15657128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The oncogenic potential of a prostate cancer-derived androgen receptor mutant.
    Shi XB; Xue L; Tepper CG; Gandour-Edwards R; Ghosh P; Kung HJ; DeVere White RW
    Prostate; 2007 May; 67(6):591-602. PubMed ID: 17262801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA).
    Lee SO; Yeon Chun J; Nadiminty N; Trump DL; Ip C; Dong Y; Gao AC
    Prostate; 2006 Jul; 66(10):1070-5. PubMed ID: 16637076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen receptor modifications in prostate cancer cells upon long-termandrogen ablation and antiandrogen treatment.
    Marques RB; Erkens-Schulze S; de Ridder CM; Hermans KG; Waltering K; Visakorpi T; Trapman J; Romijn JC; van Weerden WM; Jenster G
    Int J Cancer; 2005 Nov; 117(2):221-9. PubMed ID: 15900601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recruitment of beta-catenin by wild-type or mutant androgen receptors correlates with ligand-stimulated growth of prostate cancer cells.
    Masiello D; Chen SY; Xu Y; Verhoeven MC; Choi E; Hollenberg AN; Balk SP
    Mol Endocrinol; 2004 Oct; 18(10):2388-401. PubMed ID: 15256534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen receptor down regulation by small interference RNA induces cell growth inhibition in androgen sensitive as well as in androgen independent prostate cancer cells.
    Hååg P; Bektic J; Bartsch G; Klocker H; Eder IE
    J Steroid Biochem Mol Biol; 2005 Aug; 96(3-4):251-8. PubMed ID: 15982869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression.
    Sun A; Tang J; Hong Y; Song J; Terranova PF; Thrasher JB; Svojanovsky S; Wang HG; Li B
    Prostate; 2008 Mar; 68(4):453-61. PubMed ID: 18196538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth.
    Yepuru M; Wu Z; Kulkarni A; Yin F; Barrett CM; Kim J; Steiner MS; Miller DD; Dalton JT; Narayanan R
    Clin Cancer Res; 2013 Oct; 19(20):5613-25. PubMed ID: 23995860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hormone status selects for spontaneous somatic androgen receptor variants that demonstrate specific ligand and cofactor dependent activities in autochthonous prostate cancer.
    Han G; Foster BA; Mistry S; Buchanan G; Harris JM; Tilley WD; Greenberg NM
    J Biol Chem; 2001 Apr; 276(14):11204-13. PubMed ID: 11063747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-redundant inhibitor of differentiation (Id) gene expression and function in human prostate epithelial cells.
    Asirvatham AJ; Schmidt MA; Chaudhary J
    Prostate; 2006 Jun; 66(9):921-35. PubMed ID: 16541417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression and role of Foxa proteins in prostate cancer.
    Mirosevich J; Gao N; Gupta A; Shappell SB; Jove R; Matusik RJ
    Prostate; 2006 Jul; 66(10):1013-28. PubMed ID: 16001449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene expression profile of mouse prostate tumors reveals dysregulations in major biological processes and identifies potential murine targets for preclinical development of human prostate cancer therapy.
    Haram KM; Peltier HJ; Lu B; Bhasin M; Otu HH; Choy B; Regan M; Libermann TA; Latham GJ; Sanda MG; Arredouani MS
    Prostate; 2008 Oct; 68(14):1517-30. PubMed ID: 18668517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paired box 2 upregulates androgen receptor gene expression in androgen-independent prostate cancer.
    Ito S; Ueda T; Ueno A; Nakagawa H; Taniguchi H; Hongo F; Kamoi K; Okihara K; Kawauchi A; Miki T
    FEBS J; 2014 Oct; 281(19):4506-18. PubMed ID: 25132193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model.
    Terada N; Shimizu Y; Kamba T; Inoue T; Maeno A; Kobayashi T; Nakamura E; Kamoto T; Kanaji T; Maruyama T; Mikami Y; Toda Y; Matsuoka T; Okuno Y; Tsujimoto G; Narumiya S; Ogawa O
    Cancer Res; 2010 Feb; 70(4):1606-15. PubMed ID: 20145136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression profiles and functional associations of endogenous androgen receptor and caveolin-1 in prostate cancer cell lines.
    Bennett NC; Hooper JD; Johnson DW; Gobe GC
    Prostate; 2014 May; 74(5):478-87. PubMed ID: 24375805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of androgen receptor in prostatic neoplasia versus hyperplasia.
    Husain I; Shukla S; Soni P; Husain N
    J Cancer Res Ther; 2016; 12(1):112-6. PubMed ID: 27072221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Wild-type but not mutant androgen receptor inhibits expression of the hTERT telomerase subunit: a novel role of AR mutation for prostate cancer development.
    Moehren U; Papaioannou M; Reeb CA; Grasselli A; Nanni S; Asim M; Roell D; Prade I; Farsetti A; Baniahmad A
    FASEB J; 2008 Apr; 22(4):1258-67. PubMed ID: 17991730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
    Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
    Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological targeting of constitutively active truncated androgen receptor by nigericin and suppression of hormone-refractory prostate cancer cell growth.
    Mashima T; Okabe S; Seimiya H
    Mol Pharmacol; 2010 Nov; 78(5):846-54. PubMed ID: 20709811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.